Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2014

View Archived Issues

Doxofylline receives FDA orphan drug status for bronchiectasis

ONC1-13B shows high efficacy in preclinical models of prostate cancer

ProTide technology applied to anticancer agents to overcome drug resistance

BioAtla grants BioMotiv worldwide rights to IL-22 antibody

Pivotal trial of LDE-225 in advanced basal cell carcinoma meets primary endpoint

CURx Pharmaceuticals enters into license agreement with Gilead Sciences

Phase III ramucirumab lung cancer trial meets primary endpoint of overall survival

Zealand Pharma prepares novel glucagon receptor agonists

Insmed provides interim update from extension study of Arikace in cystic fibrosis

Omeros doses first patient in second phase II trial of OMS-824

Oritavancin NDA accepted by FDA for filing

Researchers at Proximagen present new PAR-2 antagonists

Preclinical results presented for RTL-1000 as a therapeutic agent for stroke

Actavis to acquire Forest Laboratories

Cellceutix submits IND for Prurisol trial, begins enrollment in phase IIb trials of brilacidin

Onconova discloses results from phase III trial of intravenous rigosertib in higher risk MDS

Nerviano Medical Sciences discloses novel JAK inhibitors

Michael J. Fox Foundation awards grant to Ezose Sciences

New H+/K+-ATPase inhibitors designed for gastrointestinal and other disorders

Bayer begins phase III COAST trial of regorafenib

Korean group prepares novel MAbs for cancer

PAK-01 enhances reperfusion and neuroprotection with no hemorrhagic transformation in vivo

Dilafor and Lee's Pharmaceutical sign license agreement for tafoxiparin in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...